Trillium Successfully Withdraws Lobbying Disclosure Resolution at Amgen
December 9, 2013: Trillium Asset Management is pleased to announce that it has withdrawn a shareholder proposal at Amgen, Inc. (NASDAQ:AMGN) following commitments from the company that will lead to greater transparency in their reporting of lobbying spending.
Trillium filed the resolution on behalf of our clients, including Social Justice Fund Northwest.
Beginning in 2014, Amgen will annually disclose its membership in trade associations along with the amounts the trade associations spend from its fees for non-deductible lobbying activities.
In addition, Amgen has committed to publish an annual list of all states where it files lobbying reports and provide links to the reports or state websites where the information can be found.
These significant and meaningful steps by Amgen are sound risk management and we commend the company for taking a leadership position in the pharmaceutical industry — and in corporate America more generally.